EP3250219A4 - Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life - Google Patents

Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life Download PDF

Info

Publication number
EP3250219A4
EP3250219A4 EP15880651.3A EP15880651A EP3250219A4 EP 3250219 A4 EP3250219 A4 EP 3250219A4 EP 15880651 A EP15880651 A EP 15880651A EP 3250219 A4 EP3250219 A4 EP 3250219A4
Authority
EP
European Patent Office
Prior art keywords
compositions
life
methods
increased half
soluble tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15880651.3A
Other languages
German (de)
French (fr)
Other versions
EP3250219A1 (en
Inventor
Rajiv DATAR
III Carl K. EDWARDS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dnx Biotech LLC
Original Assignee
Dnx Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnx Biotech LLC filed Critical Dnx Biotech LLC
Publication of EP3250219A1 publication Critical patent/EP3250219A1/en
Publication of EP3250219A4 publication Critical patent/EP3250219A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0081—Reaction with amino acids, peptides, or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
EP15880651.3A 2015-01-28 2015-12-21 Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life Withdrawn EP3250219A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562108825P 2015-01-28 2015-01-28
PCT/US2015/067055 WO2016122806A1 (en) 2015-01-28 2015-12-21 Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life

Publications (2)

Publication Number Publication Date
EP3250219A1 EP3250219A1 (en) 2017-12-06
EP3250219A4 true EP3250219A4 (en) 2018-10-03

Family

ID=56544143

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15880651.3A Withdrawn EP3250219A4 (en) 2015-01-28 2015-12-21 Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life

Country Status (6)

Country Link
US (1) US20180028612A1 (en)
EP (1) EP3250219A4 (en)
JP (1) JP2018508496A (en)
AU (1) AU2015380301B2 (en)
CA (1) CA2975312A1 (en)
WO (1) WO2016122806A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106686446B (en) * 2015-11-05 2020-07-14 腾讯科技（北京）有限公司 Content projection method and mobile terminal
CN116270551A (en) 2016-07-27 2023-06-23 考里安有限责任公司 Composition for in-situ conversion from salt to neutral drug, transdermal patch and application
TWI815194B (en) 2020-10-22 2023-09-11 美商基利科學股份有限公司 INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE
CN114478709A (en) * 2020-11-13 2022-05-13 成都奥达生物科技有限公司 Long-acting hepatitis virus entry inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989147B2 (en) * 1996-07-09 2006-01-24 Amgen Inc. Truncated soluble tumor necrosis factor type-I and type-II receptors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261801B1 (en) * 1997-01-14 2001-07-17 Human Genome Sceineces, Inc. Nucleic acids encoding tumor necrosis factor receptor 5

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989147B2 (en) * 1996-07-09 2006-01-24 Amgen Inc. Truncated soluble tumor necrosis factor type-I and type-II receptors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PAUL L DEANGELIS: "Heparosan, a promising 'naturally good' polymeric conjugating vehicle for delivery of injectable therapeutics", EXPERT OPINION ON DRUG DELIVERY, vol. 12, no. 3, 3 November 2014 (2014-11-03), GB, pages 349 - 352, XP055501723, ISSN: 1742-5247, DOI: 10.1517/17425247.2015.978282 *
See also references of WO2016122806A1 *

Also Published As

Publication number Publication date
AU2015380301B2 (en) 2020-04-23
WO2016122806A8 (en) 2017-08-31
AU2015380301A1 (en) 2017-09-14
US20180028612A1 (en) 2018-02-01
CA2975312A1 (en) 2016-08-04
JP2018508496A (en) 2018-03-29
EP3250219A1 (en) 2017-12-06
WO2016122806A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
EP3262071B8 (en) Method of using anti-cd79b immunoconjugates
EP3092256A4 (en) Compounds and compositions for immunotherapy
EP3152319A4 (en) Methods and compositions for nuclease design
EP3102673A4 (en) Methods and compositions for treatment of a beta thalessemia
EP3139920A4 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
EP3096759A4 (en) Modified release formulations of pridopidine
EP3236903A4 (en) Methods and formulations for transdermal administration
EP3380622A4 (en) Methods and compositions for engineering immunity
EP3224012A4 (en) Methods and compositions for concrete production
EP3240571A4 (en) Formulation of aglycosylated therapeutic antibodies
EP3102200A4 (en) Therapeutic compounds and compositions
EP3345939A4 (en) Powder mixture
EP3096757A4 (en) Apilimod compositions and methods for using same
EP3094606A4 (en) Cement compositions, structures, and methods of use
EP3145893A4 (en) Combined set-delayed cement compositions
EP3253389A4 (en) Apilimod compositions and methods for using same
EP3207093A4 (en) Resin compositions and methods for making and using same
EP3215132A4 (en) Methods of administering amantadine compositions
EP3116489A4 (en) Methods and compositions for transdermal delivery
EP3110422A4 (en) Compositions and methods for the delivery of therapeutics
EP3183243A4 (en) Organotellurium compounds, compositions and methods of use thereof
EP3207945A4 (en) Sustained release formulation of metformin and method for preparing same
EP3250219A4 (en) Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life
EP3203995A4 (en) Compositions and methods for the delivery of therapeutics
EP3178471A4 (en) Preparation method of drug-containing sustained release microparticles

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170828

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180904

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/06 20060101ALI20180829BHEP

Ipc: A61P 3/00 20060101ALI20180829BHEP

Ipc: A61K 38/17 20060101AFI20180829BHEP

Ipc: A61K 47/64 20170101ALI20180829BHEP

Ipc: C07K 14/715 20060101ALI20180829BHEP

Ipc: C07K 14/525 20060101ALI20180829BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190702